These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8781654)

  • 1. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases.
    Leveugle B; Faucheux BA; Bouras C; Nillesse N; Spik G; Hirsch EC; Agid Y; Hof PR
    Acta Neuropathol; 1996; 91(6):566-72. PubMed ID: 8781654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine.
    Thibaut F; Faucheux BA; Marquez J; Villares J; Menard JF; Agid Y; Hirsch EC
    Brain Res; 1995 Sep; 692(1-2):233-43. PubMed ID: 8548309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?
    Mouatt-Prigent A; Karlsson JO; Agid Y; Hirsch EC
    Neuroscience; 1996 Aug; 73(4):979-87. PubMed ID: 8809817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.
    Faucheux BA; Nillesse N; Damier P; Spik G; Mouatt-Prigent A; Pierce A; Leveugle B; Kubis N; Hauw JJ; Agid Y
    Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9603-7. PubMed ID: 7568181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease.
    Kastner A; Hirsch EC; Herrero MT; Javoy-Agid F; Agid Y
    J Neurochem; 1993 Sep; 61(3):1024-34. PubMed ID: 8103078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease.
    Faucheux BA; Hauw JJ; Agid Y; Hirsch EC
    Brain Res; 1997 Feb; 749(1):170-4. PubMed ID: 9070646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of 125I-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease.
    Faucheux BA; Hirsch EC; Villares J; Selimi F; Mouatt-Prigent A; Javoy-Agid F; Hauw JJ; Agid Y
    J Neurochem; 1993 Jun; 60(6):2338-41. PubMed ID: 8492137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis.
    Leveugle B; Spik G; Perl DP; Bouras C; Fillit HM; Hof PR
    Brain Res; 1994 Jul; 650(1):20-31. PubMed ID: 7953673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
    Pearce RK; Owen A; Daniel S; Jenner P; Marsden CD
    J Neural Transm (Vienna); 1997; 104(6-7):661-77. PubMed ID: 9444566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transferrin receptors in the parkinsonian midbrain.
    Morris CM; Candy JM; Omar S; Bloxham CA; Edwardson JA
    Neuropathol Appl Neurobiol; 1994 Oct; 20(5):468-72. PubMed ID: 7845532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of non-phosphorylated neurofilament immunoreactivity, with preservation of tyrosine hydroxylase, in surviving substantia nigra neurons in Parkinson's disease.
    Gai WP; Vickers JC; Blumbergs PC; Blessing WW
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1039-46. PubMed ID: 7916375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.
    Counihan TJ; Penney JB
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):164-9. PubMed ID: 9703165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.
    Chinaglia G; Alvarez FJ; Probst A; Palacios JM
    Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
    Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
    Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
    Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
    J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Morphochemical changes in the substantia nigra cellular structures in Parkinson's disease].
    Salkov VN; Khudoerkov RM; Voronkov DN; Sobolev VB; Kutukova KA
    Arkh Patol; 2017; 79(5):3-9. PubMed ID: 29027522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease.
    McRitchie DA; Cartwright HR; Halliday GM
    Exp Neurol; 1997 Mar; 144(1):202-13. PubMed ID: 9126172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microtopography of D1 dopaminergic binding sites in the human substantia nigra: an autoradiographic study.
    Thibaut F; Hirsch EC; Raisman R; Javoy-Agid F; Agid Y
    Neuroscience; 1990; 37(2):387-98. PubMed ID: 1983469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.